RECITALS:Product Development and License Agreement • September 6th, 2005 • Elite Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New Jersey
PRODUCT DEVELOPMENT AND LICENSE AGREEMENTProduct Development and License Agreement • July 18th, 2007 • Amedica Corp • Surgical & medical instruments & apparatus • Delaware
THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”) is made and entered into this 20th day of December, 2006 (“Effective Date”), by and between AMEDICA CORPORATION, having its principal offices at 615 Arapeen Drive, Salt Lake City, Utah 84108 (“AMEDICA”), and DYTECH CORPORATION LTD, having its principal offices at Stopes Road, Stannington, Sheffield, S6 6BW England (“DYTECH”).
RECITALSProduct Development and License Agreement • December 27th, 2005 • Authentidate Holding Corp • Services-computer integrated systems design • Colorado
CONFIDENTIAL TREATMENT REQUESTED: Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Such redacted...Product Development and License Agreement • February 26th, 2010 • Biovail Corp International • Pharmaceutical preparations
BIOVAIL LABORATORIES INCORPORATED a Barbados corporation incorporated under the International Business Companies Act, 1991-24, whose head office is
FIRST AMENDMENT DATED AS OF DECEMBER 4, 2006 TO PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN NASTECH PHARMACEUTICAL COMPANY INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC. DATED AS OF JANUARY 27, 2006Product Development and License Agreement • March 7th, 2007 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
This First Amendment to the Product Development and License Agreement (the “First Amendment”) is entered into as of December 4, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (“P&G”), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (“Nastech”), as an amendment to the Product Development and License Agreement (the “Agreement”) entered into as of January 27, 2006 by and between P&G and Nastech. All capitalized terms used herein shall have the meanings given in the Agreement.
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN SHIRE LLC AND DURAMED PHARMACEUTICALS, INC. DATED AS OF AUGUST 14, 2006Product Development and License Agreement • November 9th, 2006 • Barr Pharmaceuticals Inc • Pharmaceutical preparations • New York
This PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is dated as of August 14, 2006 by and among SHIRE LLC, a Kentucky limited liability company having a principal place of business at 9200 Brookfield Court, Florence, Kentucky 41042 (together with its Affiliates, “Shire”), SHIRE plc, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of Section 15.10 of this Agreement, and DURAMED PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”). Shire and Duramed are sometimes referred to herein individually as a “Party” and together as the “Parties”.
Amendment #1 To Amended and Restated Product Development and License Agreement between Aventis Pharmaceuticals Inc. and Coley Pharmaceutical Group, Inc.Product Development and License Agreement • April 20th, 2005 • Coley Pharmaceutical Group, Inc. • Massachusetts
This Amendment #1 to the Amended and Restated Product Development and License Agreement (“Amendment #1”), is made as of August 6, 2003 (the “Effective Date”), by and between COLEY PHARMACEUTICAL GROUP, INC., a Delaware corporation having a place of business at Wellesley Gateway, 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481 (“Coley”), and AVENTIS PHARMACEUTICALS INC., a Delaware corporation having a place of business at 200 Crossing Boulevard, P.O. Box 6890, Bridgewater, New Jersey 08807 (“Aventis”) (each individually a “Party” and collectively the “Parties”).
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN NASTECH PHARMACEUTICAL COMPANY INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC. DATED AS OF JANUARY 27, 2006Product Development and License Agreement • February 2nd, 2006 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
This Product Development and License Agreement (the “Agreement”) is entered into as of January 27, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (“P&G”), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (“Nastech”).
AMENDMENT TO PRODUCT DEVELOPMENT AND LICENSE AGREEMENTProduct Development and License Agreement • May 7th, 2009 • Shire PLC • Pharmaceutical preparations
This Amendment to the Product Development and License Agreement, effective as of February 24, 2009, is by and between Shire LLC, Shire Biopharmaceuticals Holdings (formerly known as Shire plc) (collectively “Shire”) and Duramed Pharmaceuticals, Inc. (“Duramed”). Shire and Duramed are referred to together as the “Parties”.
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN DYAX CORP. AND CMIC CO. LTD. DATED AS OF SEPTEMBER 28, 2010 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission.Product Development and License Agreement • November 2nd, 2010 • Dyax Corp • Services-commercial physical & biological research • Massachusetts
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN SHIRE LLC AND DURAMED PHARMACEUTICALS, INC. DATED AS OF AUGUST 14, 2006Product Development and License Agreement • November 7th, 2006 • Shire PLC • Pharmaceutical preparations • New York
This PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is dated as of August 14, 2006 by and among SHIRE LLC, a Kentucky limited liability company having a principal place of business at 9200 Brookfield Court, Florence, Kentucky 41042 (together with its Affiliates, “Shire”), SHIRE plc, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of Section 15.10 of this Agreement, and DURAMED PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“Duramed”). Shire and Duramed are sometimes referred to herein individually as a “Party” and together as the “Parties”.
